2022
Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials
Simader FA, Howard JP, Ahmad Y, Saleh K, Naraen A, Samways JW, Mohal J, Reddy RK, Kaza N, Keene D, Shun-Shin MJ, Francis DP, Whinnett ZI, Arnold AD. Catheter ablation improves cardiovascular outcomes in patients with atrial fibrillation and heart failure: a meta-analysis of randomized controlled trials. EP Europace 2022, 25: 341-350. PMID: 36305545, PMCID: PMC9934993, DOI: 10.1093/europace/euac173.Peer-Reviewed Original ResearchConceptsHeart failure hospitalizationCatheter ablationHeart failureMedical therapyFailure hospitalizationAtrial fibrillationCardiovascular outcomesPrimary analysisPre-specified primary endpointAtrial fibrillation catheter ablationCause mortalityPrimary endpointSecondary endpointsLower riskPatientsTherapyHospitalizationFibrillationTrialsMortalityLow heterogeneityAblationEndpointOutcomesFailure
2018
Reply to: Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Francis D, Sen S. Reply to: Assessing the quality of evidence supporting patent foramen ovale closure over medical therapy after cryptogenic stroke. European Heart Journal 2018, 39: 3620-3620. PMID: 30137277, DOI: 10.1093/eurheartj/ehy498.Peer-Reviewed Original ResearchP716PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Petraco R, Sutaria N, Malik I, Mayet J, Francis D, Sen S. P716PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials. European Heart Journal 2018, 39: ehy564.p716. DOI: 10.1093/eurheartj/ehy564.p716.Peer-Reviewed Original Research2 PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials
Ahmad Y, Howard J, Arnold A, Shun-Shin M, Cook C, Malik I, Mayet J, Francis D, Sen S. 2 PFO closure is superior to medical therapy for cryptogenic stroke: a meta-analysis of randomised controlled trials. Heart 2018, 104: a2. DOI: 10.1136/heartjnl-2018-bcs.2.Peer-Reviewed Original ResearchMedical therapyCryptogenic strokeDevice closureAtrial fibrillationRecurrent strokePFO closureNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointPrevention of strokeEfficacy endpointFurther strokeSafety endpointTreat basisPatent foramenPatientsTherapyStrokePFOTrialsEndpointPreventionClosurePatent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials
Ahmad Y, Howard JP, Arnold A, Shin MS, Cook C, Petraco R, Demir O, Williams L, Iglesias JF, Sutaria N, Malik I, Davies J, Mayet J, Francis D, Sen S. Patent foramen ovale closure vs. medical therapy for cryptogenic stroke: a meta-analysis of randomized controlled trials. European Heart Journal 2018, 39: 1638-1649. PMID: 29590333, PMCID: PMC5946888, DOI: 10.1093/eurheartj/ehy121.Peer-Reviewed Original ResearchConceptsMedical therapyCryptogenic strokeDevice closurePFO closureAtrial fibrillationRecurrent strokeLarge shuntPatent foramenNew-onset atrial fibrillationRisk of AFOnset atrial fibrillationPrimary safety endpointPrimary efficacy endpointAtrial septal aneurysmPrevention of strokeSignificant reductionEfficacy endpointFurther strokeSafety endpointTreat basisSeptal aneurysmSmall shuntPatientsTherapyStrokeOptimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis
Ahmad Y, Demir O, Rajkumar C, Howard JP, Shun-Shin M, Cook C, Petraco R, Jabbour R, Arnold A, Frame A, Sutaria N, Ariff B, Kanaganayagam G, Francis D, Mayet J, Mikhail G, Malik I, Sen S. Optimal antiplatelet strategy after transcatheter aortic valve implantation: a meta-analysis. Open Heart 2018, 5: e000748. PMID: 29387433, PMCID: PMC5786926, DOI: 10.1136/openhrt-2017-000748.Peer-Reviewed Original ResearchTranscatheter aortic valve implantationDual antiplatelet therapyAortic valve implantationAspirin monotherapyAntiplatelet therapyTAVI centresValve implantationBenefits of DAPTSystematic reviewOptimal antiplatelet strategyIncidence of strokeAntiplatelet useDAPT durationAdverse eventsAntiplatelet strategiesMedian durationInternational guidelinesMonotherapySuitable studiesTherapyElectronic surveyMetaregressionStrokeDeathDuration
2017
TCT-120 Aspirin is equivalent to dual antiplatelet therapy after transcatheter aortic valve replacement: a meta-analysis of 11,781 patients
Ahmad Y, Demir O, Howard J, Shun-Shin M, Cook C, Petraco R, Al-Lamee R, Jabbour R, Sutaria N, Ariff B, Kanaganayagam G, Chukwuemeka A, Anderson J, Francis D, Mayet J, Davies J, Mikhail G, Malik I, Sen S. TCT-120 Aspirin is equivalent to dual antiplatelet therapy after transcatheter aortic valve replacement: a meta-analysis of 11,781 patients. Journal Of The American College Of Cardiology 2017, 70: b54. DOI: 10.1016/j.jacc.2017.09.178.Peer-Reviewed Original ResearchTCT-269 PFO Closure is Superior to Medical Therapy for Cryptogenic Stroke: a meta-analysis of randomised controlled trials
Ahmad Y, Shun-Shin M, Howard J, Cook C, Petraco R, Demir O, Mikhail G, Sutaria N, Baker C, Davies J, Mayet J, Francis D, Malik I, Sen S. TCT-269 PFO Closure is Superior to Medical Therapy for Cryptogenic Stroke: a meta-analysis of randomised controlled trials. Journal Of The American College Of Cardiology 2017, 70: b111. DOI: 10.1016/j.jacc.2017.09.346.Peer-Reviewed Original ResearchAcute myocardial infarction and stroke secondary to valve thrombosis following transcatheter aortic valve replacement—what can happen when antiplatelet agents are stopped
Lam MC, Kanaganayagam G, Ahmad Y, Fertleman M, Ariff B. Acute myocardial infarction and stroke secondary to valve thrombosis following transcatheter aortic valve replacement—what can happen when antiplatelet agents are stopped. Quantitative Imaging In Medicine And Surgery 2017, 7: 605-607. PMID: 29184771, PMCID: PMC5682404, DOI: 10.21037/qims.2017.10.04.Peer-Reviewed Original ResearchTranscatheter aortic valve replacementDual antiplatelet therapyAortic valve replacementValve replacementAortic stenosisSevere aortic stenosisCoronary artery bypassPast medical historyAcute myocardial infarctionAntiplatelet therapyArtery bypassAntiplatelet agentsPost procedureMedical historyMyocardial infarctionMonthsVomitingInfarctionStenosisThrombosisPatientsAdmissionBypassTherapyStroke
2015
CRT-177 Why Is Demonstrating A Mortality Reduction For New STEMI Therapies Increasingly Difficult With Conventional RCTs? A Meta-analysis Of 10,375 Patients In Thrombus Aspiration Trials
Keene D, Ahmad Y, Francis D. CRT-177 Why Is Demonstrating A Mortality Reduction For New STEMI Therapies Increasingly Difficult With Conventional RCTs? A Meta-analysis Of 10,375 Patients In Thrombus Aspiration Trials. JACC Cardiovascular Interventions 2015, 8: s31. DOI: 10.1016/j.jcin.2014.12.118.Peer-Reviewed Original Research
2013
Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation
Myat A, Ahmad Y, Haldar S, Tantry US, Redwood SR, Gurbel PA, Lip GY. Is bleeding a necessary evil? The inherent risk of antithrombotic pharmacotherapy used for stroke prevention in atrial fibrillation. Expert Review Of Cardiovascular Therapy 2013, 11: 1029-1049. PMID: 23984927, DOI: 10.1586/14779072.2013.815423.Peer-Reviewed Original ResearchConceptsStroke preventionAntithrombotic therapyAntithrombotic agentsNovel oral anticoagulation agentsAtrial fibrillation guidelinesOral anticoagulation agentsDrug-drug interactionsDirect antidoteAF patientsAnticoagulation monitoringAnticoagulation agentsAtrial fibrillationAbsolute riskAntithrombotic pharmacotherapyRelative riskLower riskStrong recommendationsPatientsThromboembolismPreventionRiskTherapyInherent risksAuthors' knowledgeAgents
2012
Stroke Prevention in Atrial Fibrillation: Where are We Now?
Ahmad Y, Lip GY. Stroke Prevention in Atrial Fibrillation: Where are We Now? Clinical Medicine Insights Cardiology 2012, 6: cmc.s8976. PMID: 22408371, PMCID: PMC3296491, DOI: 10.4137/cmc.s8976.Peer-Reviewed Original ResearchStroke preventionAtrial fibrillationOnly successful therapyLow-risk patientsBetter risk stratificationStroke prophylaxisRisk stratificationCommon arrhythmiaNovel anticoagulantsSuccessful therapyWarfarinPatientsGreater mortalityPreventionFibrillationAF researchEffective alternativeNew optionsAnticoagulationImproved management strategiesProphylaxisAnticoagulantsArrhythmiasTherapyMajor progress